Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. - Powerful Science for Life
Corporate - Media & Press - Press Release
Visiting Scholar Dr. Mark Schena co-authors MAQC publication.
Sunnyvale, CA, September 12, 2006 – On September 8th, Arrayit announced that its Visiting Scholar Dr. Mark Schena, the originator of microarray technology, co-authored a scientific paper reporting on a study organized by the United States Food and Drug Administration to establish quality control standards for DNA microarrays. The MicroArray Quality Control or MAQC project, led by microarray enthusiast and FDA scientist Dr. Leming Shi, featured 137 researchers from 51 different organizations. The publication entitled “The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements” appeared in the prestigious scientific journal Nature Biotechnology (Nature Biotech. 24, 1151-1161, 2006). The manuscript represents an important step forward in terms of using DNA microarrays and microarray data for medical decision-making. Dr. Schena and his colleagues at Stanford University published the first paper on microarrays in Science magazine in 1995 (Schena et al., Quantitative monitoring of gene expression patterns with a complementary DNA microarray, Science 270, 467-470, 1995). Since the publication of Dr. Schena’s 95’ Science paper, the microarray field has expanded to include more than 20,000 scientific publications and has grown into a billion dollar commercial endeavor in which TeleChem’s ArrayIt® Division holds a leading position. Over the next five years, ArrayIt® anticipates a further expansion of the microarray industry to $5-10 billion dollars annually, and the company expects to play an increasingly important role with its strong IP position and widely used platform and products.
During a recent press conference, Dr. Schena shared his views on the microarray field and MACQ study. “When we published the Science paper in 1995, many in the scientific community were skeptical that microarrays would be widely used because at the time there were no commercial tools, the anticipated cost of the technology was high, and the assays were believed to lack the requisite precision required for diagnostics. Since 1995, my colleagues and I have worked tirelessly in meetings, speeches, books and publications to expand the microarray field as quickly and efficiently as possible. A decade later, with the assistance of thousands of academic, government, and commercial laboratories, microarrays have become cornerstones of basic research and drug discovery, and are moving quickly towards acceptance in clinical medicine and diagnostics. The recent MAQC study represents an important step forward in terms of validating many different microarray platforms for clinical use, and I am pleased to say that the findings are consistent with a prediction we made eight years ago [Schena et al., Microarrays: biotechnology's discovery platform for functional genomics, Trends in Biotechnology 16, 301-306, 1998] in which we foresaw a large microarray industry featuring photolithography, contact printing, and ink-jetting as widely used manufacturing methods [Fig. 1]. We also predicted that some newer approaches might also be used, so in this respect I am pleased with the success of Illumina’s bead platform, which meets the four basic criteria required of a microarray. My hope is that future MAQC studies will focus on additional types of microarrays including those containing proteins, peptides, antibodies, patient samples and other types of molecules. Going forward, it is essential to have the support of the FDA.”
Figure 1. Illustration from Schena et al. 1998 depicting the three main microarray manufacturing technologies that the authors predicted would be used by the modern microarray industry. Reprinted with permission from Elsevier Science Ltd. (Oxford, UK). Figure 2 from Schena et al., Microarrays: biotechnology's discovery platform for functional genomics, Trends in Biotechnology 16, 301-306, 1998.
Company Public Relations Director Paul K. Haje commented further at the MAQC press conference. “Our flagship whole genome product H25K is a 25,000 gene second-generation microarray that allows researchers to explore up to 5,000 human genes not available on other platforms [Fig. 2]. As we fine-tune and expand our applications protocols, customers can expect increasingly valuable data for mapping, gene expression profiling, CGH and other studies. We believe that our patented printing technology [U.S. 6,101,946] and proprietary oligonucleotide designs allow us to deliver unprecedented gene content to our customers. H25K is allowing researchers to drill deeper into the human genome.”
Figure 2. Shown is a comparison of the oligonucleotide (probe) mapping results for the ArrayIt® H25K whole human genome microarray (right) versus the other commercial platforms. Percentages correspond to matches to NM or AceView transcripts. The data were provided courtesy of Dr. Jean Thierry-Mieg from the National Center for Biotechnology Information (NCBI).
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley. Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications. Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services. The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.
Copyright 1993-2019 Arrayit Corporation. All rights reserved.